Navigate Fool.com
Will POZN beat
the market?


Community Rating: 2 Stars: Unattractive

8.12 0.05 (0.62%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.08
Previous Close $8.07
Daily Range $8.05 - $8.25
52-Week Range $4.92 - $9.90
Market Cap $250.5M
P/E Ratio -29.89
Dividend (Yield) $0.00 (0.0%)
Volume 16,115
Average Daily Volume 332,155
Current FY EPS $0.62

How do you think POZN
will perform against the market?

Top POZN Bull/Bear Pitches


valuefocusgroup (< 20)
Submitted April 5, 2011

Price/earnings of 7.50, market cap of 170.45 million, Debt/equity of zero, Return on Invested Capital (TTM) of 48.89, based in North Carolina, United States, focus on acute pain treatment.

0 Replies Reply Report this Post

pbtoau78 (< 20)
Submitted May 12, 2010

This is a classic example of a false moat. Building off zzlangerhans' example of treximet, Vimovo which is falsely being labeled as a &quot;pain drug&quot; (NSAIDs are fundamentally anti-inflammatory … More

2 Replies Reply Report this Post

News & Commentary Rss Feed

Up 31%: Why Pernix Therapeutics Surprised Investors

Why this move up makes sense.

Why POZEN Inc. Shares Were Slammed

POZEN shares hit the sales rack after receiving unwelcome news from the Food and Drug Administration. Find out why this may not be as bad as it appears on the surface.

3 Biotech Stocks With Upcoming Catalysts

BioDelivery Sciences International, Keryx Biopharmaceuticals, and Pozen Inc. all have near-term regulatory catalysts. Which, if any, are worth keeping tabs on?

3 Stocks to Get on Your Watchlist

POZEN, Lionbridge Technologies, and Westmoreland Coal are this week's must-watch stocks.

Sector Update: Healthcare Stocks Higher Pre-Market; Pozen Rises on Q4 Results

Sector Update: Healthcare

Pozen's Wagon is Tied to Horizon and Sanofi

Horizon's (HZNP) purchase of AstraZeneca's (AZN) rights to Pozen's VImovo and Sanofi's bet on Pozen's cardiovascular drug have big implications for Pozen's future.

Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014

A big mid-stage disappointment sent Avanir's (AVNR) shares tumbling, but the future may not be as bad as some fear.

Pozen, Inc. (POZN) Ex-Dividend Date Scheduled for December 31, 2013

Sector Update: Healthcare Stocks Mixed Pre-Market; TSRO Sinks 7% on Phase 3 Results of Rolapitant

See More POZN News...





POZEN, Inc. (POZN) Description

A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. Website: http://www.pozen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks